Clinical Trial Update: Safety, Tolerability, and Pharmacokinetics of Single Doses of APN1125 in Healthy Normal Subjects [Phase 1]

View source ↗

Summary

Phase 1 safety, tolerability, and pharmacokinetics study of single doses of APN1125 in healthy normal subjects has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• APN1125

Snippet

Sponsor: CoMentis | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED